Literature DB >> 2858193

Reversible ipecac myopathy.

J E Mateer, B J Farrell, S S Chou, L Gutmann.   

Abstract

The abuse of ipecac syrup for three years resulted in painless, nonfatigable, chiefly proximal weakness in a 27-year-old woman. Electromyography (EMG) and a muscle biopsy revealed features of a myopathy similar to those previously reported in experimental emetine myopathy. Clinical weakness and EMG abnormalities improved after discontinuation of ipecac administration. A direct toxic action of ipecac (acting through its active alkaloid, emetine hydrochloride) on muscle fibers seemed to be responsible for the weakness in this patient.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 2858193     DOI: 10.1001/archneur.1985.04060020106024

Source DB:  PubMed          Journal:  Arch Neurol        ISSN: 0003-9942


  8 in total

Review 1.  Clinical features, pathogenesis and management of drug-induced rhabdomyolysis.

Authors:  C Köppel
Journal:  Med Toxicol Adverse Drug Exp       Date:  1989 Mar-Apr

2.  Myopathy from surreptitious ipecac ingestion.

Authors:  N L Rosenberg; S P Ringel
Journal:  West J Med       Date:  1986-09

3.  Cardiotoxicity of emetine dihydrochloride by calcium channel blockade in isolated preparations and ventricular myocytes of guinea-pig hearts.

Authors:  R Lemmens-Gruber; A Karkhaneh; C Studenik; P Heistracher
Journal:  Br J Pharmacol       Date:  1996-01       Impact factor: 8.739

Review 4.  Different Aspects of Emetine's Capabilities as a Highly Potent SARS-CoV-2 Inhibitor against COVID-19.

Authors:  Mehdi Valipour
Journal:  ACS Pharmacol Transl Sci       Date:  2022-05-23

5.  Experimental emetine myopathy: enzyme histochemical, electron microscopic, and immunomorphological studies.

Authors:  N J Hopf; H H Goebel
Journal:  Acta Neuropathol       Date:  1993       Impact factor: 17.088

6.  Ultrastructural pathology in emetine-induced myopathy.

Authors:  L Halbig; L Gutmann; H H Goebel; J F Brick; S Schochet
Journal:  Acta Neuropathol       Date:  1988       Impact factor: 17.088

7.  Ipecac myopathy and cardiomyopathy.

Authors:  L P Dresser; E W Massey; E E Johnson; E Bossen
Journal:  J Neurol Neurosurg Psychiatry       Date:  1993-05       Impact factor: 10.154

8.  Reversible emetine-induced myopathy with ECG abnormalities: a toxic myopathy.

Authors:  T Kuntzer; J Bogousslavsky; J P Deruaz; R Janzer; F Regli
Journal:  J Neurol       Date:  1989-05       Impact factor: 4.849

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.